Damian Slizys, Chemistry Partner of FB Rice, has written an article on the Australian Senate's gene patent inquiry. Appearing in Patent Docs, an online biotechnology and pharmaceutical patent law and news blog, the article discusses the possible consequences to "the established grounds of invalidity under Australian law". To read the full article, click here.*
 
*Since being published, the Senate inquiry has now been put back to 2 September 2010.